Osaka, Japan – Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found. The group irradiated a mammalian cell culture medium with non-thermal atmospheric-pressure plasma to produce PAM and conducted in vitro tests using human cells and...
Latest News
Osaka, Japan – It might start simply, with a cough or sneeze…but in some cases, the flu virus can make its way to your brain, causing serious symptoms or even death through a disease known as influenza-associated encephalopathy (IAE). Now, in a study published in Acta Neuropathologica, researchers have revealed...
PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ — Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer’s disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation...
Nantes – OSE Immunotherapeutics (FR0012127173) and the French cooperative group ARCAGY-GINECO today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer...
Compared with afatinib, treatment with osimertinib demonstrates better survival outcomes for patients with T790M-positive non-small cell lung cancer (NSCLC) that does not initially respond to initial epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), according to study results published in BMC Pulmonary Medicine. A team of investigators in China conducted a...
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program. Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment...
PRINCETON, N.J. — Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced new analyses from the Phase 3 VISIONARY trial evaluating VOYXACT® (sibeprenlimab-szsi) in adults with IgA nephropathy (IgAN) at risk for disease progression, demonstrating clinically meaningful improvements across key markers of IgAN. These data, presented at the 2026 ISN...
PRINCETON, N.J. & TOKYO, Japan — Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® (sibeprenlimab-szsi) demonstrated statistically significant stabilization of kidney function, with evidence of improvement over two years, as assessed by annualized...
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to placebo The safety profile of sibeprenlimab was favorable and consistent with previously reported data Immunoglobulin A nephropathy is a progressive, immune-mediated, chronic kidney...
Norman, Oklahoma – Researchers at OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences have embarked on a revolutionary new research study that could improve the detection of a deadly disease — pancreatic cancer — and give patients a chance to live longer, healthier lives. The research...